Literature DB >> 21968931

The CHRNA5-A3-B4 gene cluster in nicotine addiction.

W H Berrettini1, G A Doyle.   

Abstract

Nicotine addiction (NA) is a common and devastating disease, such that the annual number of deaths (world-wide) from tobacco-related diseases will double from 5 million in the year 2000 to 10 million in 2020. Nicotine is the only substance in tobacco which animals and humans will self-administer. NA, as a lifetime diagnosis, has been assessed in various approaches, including the concept of cigarettes per day (CPD). Other assessments of NA are somewhat more comprehensive, such as the Fagerstrom Test for Nicotine Dependence or the American Psychiatric Association's Diagnostic and Statistical Manual (fourth edition) diagnosis of nicotine dependence. These different measures have moderate agreement with one another. Twin, family and adoption studies have shown that these different assessments of NA have substantial heritability (that fraction of risk attributable to genetic factors). The heritability of NA has been estimated at 50-75%, depending on the definition and the population under study. DNA-based studies of NA have been somewhat successful in identifying a common haplotype, which increases risk for NA among European-origin populations. This haplotype explains a small amount of variance, accounting for ∼1 CPD, and it includes the α5 and the α3 nicotinic receptor subunit genes (CHRNA5 and CHRNA3). The review will focus on this implicated region. In this risk region, there is a common (among European-origin people) mis-sense single-nucleotide polymorphism in the CHRNA5 gene (D398N), which changes a conserved amino acid from aspartic acid to asparagine. The risk allele (398N) confers decreased calcium permeability and more extensive desensitization, according to in vitro cellular studies, raising the possibility that a positive allosteric modulator of the (α4β2)(2)α5 type of nicotinic receptor might have therapeutic potential in NA. There are other genetic influences on NA in this region, apart from the mis-sense variant, and additional biological experiments must be done to understand them.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21968931     DOI: 10.1038/mp.2011.122

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  38 in total

Review 1.  Nicotinic acetylcholine receptors: upregulation, age-related effects and associations with drug use.

Authors:  W E Melroy-Greif; J A Stitzel; M A Ehringer
Journal:  Genes Brain Behav       Date:  2015-12-23       Impact factor: 3.449

2.  Functional characterization of SNPs in CHRNA3/B4 intergenic region associated with drug behaviors.

Authors:  Amber V Flora; Cristian A Zambrano; Xavier Gallego; Jill H Miyamoto; Krista A Johnson; Katelyn A Cowan; Jerry A Stitzel; Marissa A Ehringer
Journal:  Brain Res       Date:  2013-07-18       Impact factor: 3.252

3.  Medial habenula output circuit mediated by α5 nicotinic receptor-expressing GABAergic neurons in the interpeduncular nucleus.

Authors:  Yun-Wei A Hsu; Lynne Tempest; Lely A Quina; Aguan D Wei; Hongkui Zeng; Eric E Turner
Journal:  J Neurosci       Date:  2013-11-13       Impact factor: 6.167

4.  Chrna5-Expressing Neurons in the Interpeduncular Nucleus Mediate Aversion Primed by Prior Stimulation or Nicotine Exposure.

Authors:  Glenn Morton; Nailyam Nasirova; Daniel W Sparks; Matthew Brodsky; Sanghavy Sivakumaran; Evelyn K Lambe; Eric E Turner
Journal:  J Neurosci       Date:  2018-06-28       Impact factor: 6.167

5.  An Adolescent Substance Prevention Model Blocks the Effect of CHRNA5 Genotype on Smoking During High School.

Authors:  David J Vandenbergh; Gabriel L Schlomer; H Harrington Cleveland; Alisa E Schink; Kerry L Hair; Mark E Feinberg; Jenae M Neiderhiser; Mark T Greenberg; Richard L Spoth; Cleve Redmond
Journal:  Nicotine Tob Res       Date:  2015-05-04       Impact factor: 4.244

6.  Differences in mechanisms underlying reinstatement of cigarette smoke extract- and nicotine-seeking behavior in rats.

Authors:  Sarah J Cross; Daisy D Reynaga; Michelle Cano; James D Belluzzi; Nurulain T Zaveri; Frances M Leslie
Journal:  Neuropharmacology       Date:  2019-11-06       Impact factor: 5.250

7.  Effectiveness of nicotinic agonists as desensitizers at presynaptic α4β2- and α4α5β2-nicotinic acetylcholine receptors.

Authors:  Charles R Wageman; Michael J Marks; Sharon R Grady
Journal:  Nicotine Tob Res       Date:  2013-09-19       Impact factor: 4.244

8.  Profound alteration in reward processing due to a human polymorphism in CHRNA5: a role in alcohol dependence and feeding behavior.

Authors:  Morgane Besson; Benoît Forget; Caroline Correia; Rodolphe Blanco; Uwe Maskos
Journal:  Neuropsychopharmacology       Date:  2019-07-09       Impact factor: 7.853

9.  Promoter IV-BDNF deficiency disturbs cholinergic gene expression of CHRNA5, CHRM2, and CHRM5: effects of drug and environmental treatments.

Authors:  Kazuko Sakata; Abigail E Overacre
Journal:  J Neurochem       Date:  2017-08-16       Impact factor: 5.372

10.  Psychological predictors of male smokeless tobacco use initiation and cessation: a 16-year longitudinal study.

Authors:  Leela R Holman; Jonathan B Bricker; Bryan A Comstock
Journal:  Addiction       Date:  2013-04-04       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.